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ARTICLE
PTTG1 Levels Are Predictive of Saracatinib Sensitivity
in Ovarian Cancer Cell Lines
I Nakachi1, BA Helfrich2, MA Spillman3, EA Mickler4, CJ Olson4, JL Rice1, CD Coldren5, LE Heasley6, MW Geraci1
and RS Stearman1,∗
Src kinase is recognized as a key target for molecular cancer therapy. However,methods to efficiently select patients responsive
to Src inhibitors are lacking. We explored the sensitivity of ovarian cancer cell lines to the Src kinase inhibitor saracatinib
to identify predictive markers of drug sensitivity using gene microarrays. Pituitary tumor transforming gene 1 (PTTG1) was
selected as a potential biomarker as mRNA levels were correlated with saracatinib resistance, as well as higher PTTG1 protein
expression. PTTG1 expression was correlated with proliferation, cell division, and mitosis in ovarian cancer tissues data sets. In
sensitive cell lines, saracatinib treatment decreased PTTG1 and fibroblast growth factor 2 (FGF2) protein levels. Downregulating
PTTG1 by siRNAs increased saracatinib sensitivity in two resistant cell lines. Our results indicate PTTG1 may be a valuable
biomarker in ovarian cancer to predict sensitivity to saracatinib, and could form the basis of a targeted prospective saracatinib
trial for ovarian cancer.
Clin Transl Sci (2016) 9, 293–301; doi:10.1111/cts.12413; published online on 20 October 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE OF THE TOPIC?
✔ Src kinase is recognized as a key target for cancer ther-
apy; however, methods to efficiently select patients most
likely to derive therapeutic benefit from Src inhibitors are
lacking.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ We explored the sensitivity of ovarian cancer cell lines to
the Src kinase inhibitor, saracatinib, and sought to identify
predictive markers related to drug sensitivity.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
✔ Saracatinib’s effect on ovarian cancer cell line prolifer-
ation was examined. We identified differentially expressed
genes correlated with saracatinib sensitivity by expression
microarrays. Pituitary tumor transforming gene 1 (PTTG1)
was selected as a potential biomarker for saracatinib sen-
sitivity, and was further validated by an independent panel
of cell lines, protein level, and siRNA approaches.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY AND TRANSLATION SCIENCE
✔ Our results indicate that PTTG1 mRNA or protein level
may be a valuable biomarker in ovarian cancer to predict
a patient’s sensitivity to saracatinib, and could form the
basis of a targeted prospective saracatinib trial for ovarian
cancer.
Ovarian cancer is the leading cause of death from gynecolog-
ical malignancy.1 Standard of care is cytoreductive surgery
followed by platinum- or taxane-based chemotherapy with
an initial response rate of at least 70% in patients with
advanced stage disease.2 However, most patients relapse
with chemotherapy-resistant disease and overall 5-year sur-
vival probability is estimated at 30%.3 Thus, the development
of novel targeted agents and drug combinations are needed
to improve the outcome of this fatal disease.
The introduction of small molecule inhibitors target-
ing specific receptor tyrosine kinases (RTKs) and their
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downstream kinases has brought a major impact on the
management of various malignancies.4–6 Among them, Src
tyrosine kinase, a “proto-oncogene” identified in the 1970s,
has been shown to be one of the most promising targets for
anticancer therapy.7,8 The aberrant activation of Src signaling
contributes to multiple aspects of tumor development such
as cell proliferation, invasion, angiogenesis, and motility in
a large number of malignancies, including ovarian cancer.2,9
The most notable characteristic of Src is its extensive
interaction with a variety of transmembrane RTKs such as
EGFR, HER2, c-Met, and other molecules.10 Through these
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interactions, Src regulates RTK signaling as a facilitator and
directly transduces survival signals to downstream effectors.
Combining a Src inhibitor with other RTK-targeted thera-
pies was demonstrated to enhance the therapeutic effi-
cacy and overcome the therapeutic resistance to anti-RTK
drugs based on preclinical studies of breast and pancreatic
cancers.11,12
The Src inhibitor saracatinib (AZD0530) in a preclinical
study showed significant growth inhibitory, antimigratory,
and antiinvasive activities in cell lines of various origins.13
In vitro, saracatinib showed <20 nM IC50 activity against
ubiquitously expressed Src as well as other Src-family
members Yes and Fyn. In addition, it has similar activ-
ity against immune cell restricted Src-family members Lck,
Lyn, and Fgr. Recently, a randomized, placebo-controlled
trial of combined paclitaxel and the Src inhibitor saraca-
tinib in platinum-resistant ovarian cancer was reported.14
The patients enrolled in this trial (35 paclitaxel vs. 69 pacli-
taxel + saracatinib) had completed at least one round of
chemotherapy (maximum = 7) and thus could have devel-
oped more difficult to treat cancers. Although the end points
(overall survival and progression-free survival) of this study
were not statistically significant, the combined treatment
group had four patients with progression-free survival at 16
months compared with zero patients in the paclitaxel only
group.
The ability of saracatinib to modify fulvestrant (an antie-
strogen) sensitivity in estrogen receptor (ERα)-positive ovar-
ian cell lines has also been studied.15 Combined treatment
of ERα-positive ovarian cancer cell lines with fulvestrant and
saracatinib increased cell cycle arrest, decreased prolifera-
tion, and lowered tumor growth in a xenograft model. In addi-
tion, this study examined 338 primary ovarian cancers, of
which 67% of the patients had detectable ERα protein, and
they found the ERα mRNA and protein levels were highly cor-
related. The ovarian cancers also exhibited a range of phos-
phorylated Src (P-Src) levels, potentially identifying patients
most likely to respond to a combined fulvestrant/saracatinib
therapy (high ERα / low P-Src phenotype). Both of these
studies suggest a molecular-based criteria to predict which
patients may benefit the most from a targeted therapy (such
as saracatinib) regimen that could lead to significantly better
outcomes than randomly enrolled patients.
In this study we sought to identify predictive biomark-
ers that correlate with saracatinib sensitivity utilizing gene
expression profiles from a panel of ovarian cancer cell
lines. We identified human pituitary tumor transforming gene
1 (PTTG1) as a candidate biomarker since a significant
difference was observed in its expression level between
saracatinib-sensitive and -resistant ovarian cancer cell lines.
PTTG1 was discovered as an oncogene in pituitary tumors,16
and it is now recognized as a multifunctional oncogene inter-
acting with a variety of signaling pathways.17 Other stud-
ies have suggested that overexpressed PTTG1 has a signif-
icant impact on the development and progression of malig-
nancies including ovarian cancer.18–20 However, its poten-
tial role as a biological marker for determining the effi-
cacy of a molecularly targeted therapy has never been
pursued.
MATERIALS AND METHODS
Cell line tissue culture
Thirteen ovarian cancer cell lines (Supplementary Table
S1) were obtained from the Gynecologic Tissue and Fluid
Bank at the University of Colorado, and authenticated using
short tandem repeat (STR) assays.21 The obtained data
were compared with available databases to confirm the cell
lines’ identities. Cells grown in complete RPMI medium 1640
(Life Technologies, Bethesda, MD) supplemented with 10%
heat-inactivated fetal bovine serum (FBS; Life Technologies)
were exposed to saracatinib (AZD0530), provided by Astra-
Zeneca (London, UK) or purchased from ApexBio (Houston,
TX).
For cell proliferation measurements, cells were plated into
96-well tissue culture plates at a density of 1,000 to 5,000
cells per well, incubated overnight in complete medium, then
exposed to increasing concentrations of saracatinib (rang-
ing from 0–10 μM). Saracatinib dissolved in DMSO was
diluted into the micromolar range with the culture medium.
DMSO diluted with the medium was used as a vehicle con-
trol. Viable cells were evaluated after exposure for 120 h by
MTT reagent (Research Products International, Mt. Prospect,
IL). The validation cell line set was assayed using the MTS
reagent (Promega, Madison, WI); side-by-side comparison
to the MTT assay gave comparable results. A 120-h treat-
ment was chosen to allow three to four cell doublings in the
presence of saracatinib. The IC50 values were calculated from
the resulting linear regression curve. These experiments were
performed three to five independent times in three to six repli-
cates for each cell line.
Gene expression profiling of ovarian cancer cell lines
Expression microarrays were run using RNA isolated from
untreated ovarian cancer cell lines growing in complete
medium. RNA stabilization, isolation, and microarray sam-
ple labeling were carried out as described before.22 Human
Gene 1.0 ST microarrays (Affymetrix, Santa Clara, CA) were
hybridized with cRNA and processed according to the manu-
facturer’s protocol. Hybridization signals and detection calls
were generated and analyzed in Partek Genomics Suite 6.6
(Partek, St. Louis, MO) using the Robust Multi-Array Average
(RMA) expression measurement. To statistically identify dif-
ferentially expressed genes, we first removed genes with low
variance (<0.15) of expression across thewhole data set, and
then used analysis of variance (ANOVA) between the saraca-
tinib sensitive and resistant groups, to calculate the P-value
for each gene. Genes with limited fold-change differences
(<1.5-fold) between sensitive and resistant groups were
removed. There were 21 genes remaining with a False Dis-
covery Rate (FDR) P-value < 0.05. The cell line gene expres-
sion data were deposited at the Gene Expression Omnibus
(GEO; accession number GSE55628). Four additional inde-
pendent data sets (GSE9891, GSE28724, GSE53418, and
E-TABM-254) were downloaded from publicly available data
repositories (GEO and Array Express, respectively). GSE9891
was used to examine PTTG1 mRNA levels in primary ovarian
cancer tissues.23 The other two data sets were composed of
ovarian cancer cell lines and were analyzed using Partek, as
described above.
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PTTG1 was transiently silenced in the ES2 and MCAS (resis-
tant) or SKOV3 (sensitive) cell lines using a combination
of two siRNAs plasmids (GI340161 and GI340164, Ori-
gene, Rockville, MD). These two siRNAs plasmids worked
individually but gave a stronger silencing effect when
cotransfected. The targeted sequence of 29 bp siRNA was
constructed in the pGFP-V-RS retroviral vectors (TG310042,
Origene). A nontargeting scramble siRNA construct
(TR30013, Origene) was used as a negative control. Parental
cells were plated in a 6-well plate at 20,000 cells per well. The
log-phase cells, at 70–90% confluence after 24-h incubation,
were transfected with PTTG1 targeting siRNA or scrambled
siRNA sequences. SiRNA was transfected into the ES2 and
SKOV3 cells with X-tremeGENE 9 and TransIT-LT1 trans-
fection reagents according to the manufacturer’s standard
protocols, respectively (Roche, Nutley, NJ, and Mirus, Madi-
son, WI). They were allowed to recover from transfection
reagent treatment for 6–8 h incubation in complete medium
before adding saracatinib. After a 96-h exposure to saraca-
tinib, the cell number was counted using a hemocytometer.
Ninety-six-h saracatinib treatment was used to balance cell
growth and protein recovery from sensitive cells. These
experiments were repeated four times under duplicate
conditions.
Western blot assays
Cells were incubated overnight and followed by treatment
with 1 μM saracatinib. After 24- or 72-h exposure, they
were washed with phosphate-buffered saline (PBS) three
times and lysed in lysis buffer (10 mM Tris-HCl pH 7.5,
150 mM NaCl, and 0.1% Triton X-100) with protease and
phosphatase inhibitor (Thermo-Scientific, Pittsburgh, PA).
Insoluble material was cleared by centrifugation. A 72-h sara-
catinib treatment was selected to balance cell growth and
protein recovery from the sensitive cell lines. The total protein
was quantified using Micro BCA Reagents (Thermo-Fisher
Scientific). Cell lysates (50 μg protein per lane) were heated
for 10 min at 95◦C in SDS-Sample Buffer containing 5%
β-mercaptoethanol. Proteins were separated on polyacry-
lamide gels and semidry transferred to Immobilon-P trans-
fer membranes (Millipore, Bedford, MA). Membranes were
blocked for 1 h in 5% nonfat dry milk (or 2% bovine serum
albumin (BSA)) in Tris-buffered saline and 0.05% Tween
20 (TBS-T) buffer, and incubated overnight with primary
antibody in TBS-T with 5% nonfat dry milk or 2% BSA.
The following primary antibodies were used: Rabbit poly-
clonal anti-PTTG1 antibody (Life Technologies, 1:100 dilu-
tion), rabbit polyclonal antiphosphorylated P-Src (Tyr416)
(1:1,000), rabbit polyclonal anti-Src (1:1,000), rabbit mono-
clonal anti-GAPDH (D16H11, 1:1,000), and mouse anti-beta-
actin (8H10D10, 1:1,000), all purchased from Cell Signaling
Technology, Beverly, MA. After washing with TBS-T three
times, membranes were incubated with secondary antibody
(anti-IgG-HRP (Pierce, Rockford, IL; 1:15,000 dilution)) for
1 h at room temperature. Blots were washed three times and
detection was carried out using enhanced chemilumines-
cence (Thermo-Scientific). Western blots were quantitated
by densitometry using ImageJ software (NIH, Bethesda,
MD).
Fibroblast growth factor 2 (FGF2) measurement by
enzyme-linked immunosorbent assay (ELISA)
After 72 h of treatment with saracatinib (0, 0.5, and 1.0 μM),
cells were washed, lysed, and quantified as described above.
Cell lysates were diluted and FGF2 concentration was mea-
sured in 96-well plate format using Human FGF basic
Quantikine HS ELISA kit (R&D Systems, Minneapolis, MN).
Cytosolic FGF2 concentration was determined following the
manufacturer’s protocol.
RESULTS
Antiproliferative effect of saracatinib on ovarian cancer
cell lines
We first evaluated the antiproliferative effect of saracatinib
treatment on a panel of 13 ovarian cancer cell lines using
MTT-based cell proliferation assays. The IC50 values ranged
from 0.53–8.22 μM (Supplementary Table S1). This cell
line panel included common pathological subtypes of ovar-
ian cancers (serous, clear cell, mucinous, endometrioid, and
undifferentiated). The saracatinib dose–response curves for
the 13 cell lines are shown in Figure 1 (listed in order of
increasing resistance). Based on the pharmacokinetic infor-
mation in a clinical trial using saracatinib,24 eight cell lines
were designated sensitive at a cutoff IC50 value of 1.0 μM,
which is a clinically attainable drug concentration.25 The
other five cell lines with higher IC50 values (2.0 μM) were
designated resistant.
Statistical identification of differentially expressed
genes
Gene expression microarrays were run for the 13 cell lines
and we performed statistical analysis to detect differentially
regulated genes between saracatinib-sensitive and -resistant
cell lines. After filtering out the genes with low variance
(<0.15), the ANOVA test between the two sensitivity groups
with a false discovery rate (FDR) P-value < 0.05 was used to
identify 21 genes whose expression levels were significantly
associated with sensitivity to saracatinib treatment (Figure 2,
Supplementary Table S2).
Correlation analysis of the gene expression levels and IC50
values using Spearman’s ranking was used as an additional
measure for identifying potential genes. This approach iden-
tified 21 genes with a correlation value of |r|  0.80 with a
P-value < 0.001 (Supplementary Table S3). Given the lim-
ited number of genes identified, pathway analysis using
DAVID (https://david.ncifcrf.gov/home.jsp) was uninforma-
tive. Four genes (PTTG1, FECH, LEPROTL1, and RPP30)
were common to both lists. Of these four genes, we selected
PTTG1 as a potential biomarker for its known role as a tumor
oncogene. PTTG1’s expression was +1.79-fold upregulated
(ANOVA test, P-value = 4.10 × 10−4) in resistant cell lines,
and it showed a positive correlation with saracatinib IC50 of
the ovarian cancer cell lines (r = +0.819; P-value = 6.20 ×
10−4).
To explore the reproducibility of the PTTG1 mRNA expres-
sion levels found in our study, we downloaded two inde-
pendent data sets (GSE28724 and E-TABM-254) to see if
the same cell lines’ PTTG1 mRNA levels followed a sim-
ilar pattern (Supplementary Figure S1, Supplementary
Table S4). Each data set had a different number of ovarian
www.wileyonlinelibrary/cts
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Figure 1 Cell growth inhibition by saracatinib treatment in ovarian cancer cell lines. Ovarian cancer cell lines were exposed to increasing
concentrations of saracatinib (0–10 μM). Cell growth was measured by MTT assays after 120 h of treatment. Cell proliferation is shown
as percentage of the untreated control. Eight cell lines were designated sensitive at a cutoff IC50 value of 1.0 μM, which is a clinically
attainable drug concentration. The other five cell lines with high IC50 values (2.0 μM) were designated resistant. Blue or red line indicates
the assignment of each cell line to sensitive or resistant group, respectively.
Figure 2 Intensity plot of differentially expressed genes associated with saracatinib sensitivity and the plot of PTTG1 expression. (a) The
red and blue colors in the intensity plot are reflective of standardized high and low gene expression, respectively. Gray color represents
relatively normal expression of a gene. The intensity of each color indicates amplitude of gene expression. Twenty-one genes that signifi-
cantly correlate to the saracatinib sensitivity are shown. See Supplementary Table S3 for more detailed gene information. (b) Differentially
expressed PTTG1 is illustrated (P-value = 4.10 × 10−4 in ANOVA test). The circles show each cell line examined. The box-and-whisker
plot shows the distribution of PTTG1 mRNA expression for the resistant and sensitive cell lines.
cancer cell lines overlapping the cell lines we tested (8 and
11 cell lines, respectively). Categorizing the cell lines into
our defined saracatinib-resistant and -sensitive groups, they
showed significant differences in PTTG1mRNA levels in both
data sets (+2.97-fold and +1.54-fold upregulation; t-test,
P-value = 0.025 and 0.0019, respectively). Using the E-
TABM-254 data set, which had seven and four sensi-
tive/resistant cell lines, the rank-based Spearman coefficient
between PTTG1 expression and saracatinib IC50 (r = +0.79;
P-value = 0.0037) was similar to what our analysis showed.
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Figure 3 Saracatinib-associated change in protein expression in sensitive and resistant cell lines. Each cell line was treated with 0 or 1
μM saracatinib for 24 h. An equal amount of cell lysate protein (50 μg) was used. P-Src: phosphorylated Src (Tyr416).
Figure 4 Downregulation of phosphorylated Src and PTTG1 proteins induced by saracatinib treatment. The reduction rates of PTTG1 (a)
and P-Src (b) levels were calculated in the comparison of untreated and treated conditions with saracatinib (24 h) in each cell line. One
micromolar saracatinib treatment was chosen based on its clinically attainable drug concentration in patients. Quantitative analysis of
protein bands was determined using ImageJ software. **PTTG1 levels: resistant –1.80± 1.81%, sensitive –52.06± 14.34%, fold reduction
(sensitive/resistant) = 28.9-fold; P-value = 0.0020. *P-Src levels: resistant –18.42 ± 18.90%, sensitive –56.37 ± 9.37%, fold reduction
(sensitive/resistant) = 3.1-fold; P-value = 0.016, t-tests between sensitive and resistant cell lines. Each bar graph is shown as mean
reduction rate ± standard deviation (%) in replicated experiments.
Independent validation of PTTG1 mRNA expression
level and saracatinib sensitivity
The Ovarian Cancer Cell Line Panel26 analyzed 39 ovarian
cancer cell lines under uniform growth conditions, complete
with DNA fingerprinting, mRNA/miRNA expression, targeted
exon sequencing, and a limited panel of drug sensitivities.
An additional seven ovarian cancer cell lines (validation
set, Supplementary Table S5), chosen from Beaufort et al.
(GEO accession GSE5341826), were used to independently
test PTTG1 level’s ability to predict saracatinib sensitivity.
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These seven ovarian cell lines had a range in PTTG1 expres-
sion and were available from commercial cell repositories.
The PTTG1 mRNA levels were measured by quantitative
reverse-transcription polymerase chain reaction (qRT-PCR)
and found to correspond to the relative ranking predicted by
their microarray data (Supplementary Figure S2). Using the
saracatinib IC50 cutoff of 1–2 μM, five out of the seven cell
lines clearly fell into their respective categories. TOV-21G
predicted resistant had a IC50 at the borderline (1.14 μM)
while OV-7 predicted resistant was sensitive (0.48 μM).
PTTG1 is differentially expressed at the protein level
We selected four and three representative cell lines from
the sensitive and resistant groups to investigate PTTG1,
Src, and P-Src protein expression levels (sensitive: DOV13,
EFO27, SKOV3, PEO1; resistant: OVCAR8, MCAS, ES2,
Figure 3). We found that the PTTG1 protein level was differ-
entially expressed among the cell lines, and conformed to the
same pattern of mRNA expression determined by microar-
ray. Specifically, baseline PTTG1 protein levels were higher
in the resistant cell lines, compared with the sensitive lines
(4.7-fold difference, t-test, P-value= 0.0006, Figure 3). In the
sensitive lines, saracatinib treatment reduced PTTG1 protein
expression, while resistant cell lines showed limited changes
(over 28-fold difference, t-test, P-value = 0.0020, Figure 4a).
Steady-state PTTG1 mRNA levels were not affected by sara-
catinib treatment, suggesting PTTG1 protein degradation is
increased in sensitive cell lines (Supplementary Figure S3).
Figure 5 The concordant responses of FGF2 and PTTG1 to sara-
catinib treatment in ovarian cancer cell lines. (a) After exposure to
saracatinib for 72 h at 0, 0.5 and 1.0 μM, cytosolic FGF2 concen-
trations were quantified by ELISA in three experiments. All graphs
are shown as mean ± standard deviation relative to each cell line’s
initial FGF2 level. (Supplementary Figure S3 shows FGF2 levels
plotted as nanogram FGF2 / milligram protein extract). (b) PTTG1
and GAPDH protein expression were evaluated by western blot.
Cell lines are presented by increasing IC50 values from left to right.
*P-value < 0.05 in t-test, ns: not significant.
Saracatinib reduces phosphorylation of the Src protein
Further experiments were completed to explore the rele-
vance of PTTG1 protein level to phosphorylated Src (Tyr416;
P-Src) inhibition by saracatinib treatment. Western blot assay
revealed that the cell lines had a range of P-Src protein
level without saracatinib addition. However, 1 μM saracatinib
treatment reduced P-Src in all the cell lines except for the
resistant cell line OVCAR8 (Figures 3, 4b). By group com-
parison, there was a 3.1-fold larger reduction of P-Src in the
sensitive cell lines than in the resistant lines (t-test, P-value
= 0.016).
PTTG1 expression in ovarian cancer tissue
Three large studies of ovarian cancer tissues were previously
published.23,27,28 Bowen et al. compared microdissected
human normal ovarian surface epithelial cells and ovarian
cancer cells by gene expression microarrays.28 They iden-
tified PTTG1 as significantly upregulated (+2.8-fold change;
FDR P-value = 0.0001) in ovarian cancer cells.28 Tothill et al.
compared tumor to neighboring stromal tissue in ovarian
cancer tissue by gene expression microarrays.23 PTTG1
was also upregulated in tumor compared with stromal
tissue (+3.7-fold change; FDR q-value = 0.0051). Within
their study23 they had low malignant potential (LMP) and
malignant ovarian cancer tissue. We found PTTG1 was
upregulated in malignant tissue (+2.0-fold change; FDR q-
value < 0.0001) compared with LMP tissue (Supplementary
Figure S4).
The Cancer Genome Atlas (TCGA: https://tcga-data.nci.
nih.gov/tcga/) focused on ovarian serous cystadenocar-
cinoma tumors (580 patients) as one of their tar-
geted cancers.27 Using the Web-based interface cBioPortal
(http://www.cbioportal.org/), we identified and downloaded
specific ovarian cancer tissue gene expression files from
the TCGA collated database, based on PTTG1 expression.
The gene expression data are normalized around the median
value found with the ovarian cancer tissue data set. Using a
PTTG1 gene expression z-score  |1.5|, 44, and 19 low and
high PTTG1-expressing tissues, respectively, were identified
(Supplementary Figure S5a). Grouping the PTTG1 gene
expression z-score  |1.5| ranking into high and low cate-
gories (+1.5 vs. -1.5) gave a 7.4x-fold change in PTTG1
expression (t-test, P-value <0.0001), somewhat larger than
the range observed within the ovarian cancer cell line
data sets. In the ovarian cancer cell lines, SNP-microarrays
showed a correlation between higher PTTG1 expression and
copy number (Supplementary Methods). There was no cor-
relation of PTTG1 expression and copy number alterations in
these selected patients (one of the high expression patients
had slight amplification, while all the other patients were
within the normal diploid value). The proximal portion of 5q
(5q11.2/5q13.1) was reported as showing a significant fre-
quency of deletion, while the distal portion containing PTTG1
(5q33.3) was diploid.27 Survival analysis demonstrated no
significant difference between the high and low PTTG1-
expressing patients (Supplementary Figure S5b).
Finally, an analysis of the correlation of gene expression
within the TCGA’s high and low PTTG1 tissues was com-
pleted (Supplementary Table S6). There was a striking pos-
itive correlation of genes (n= 142 genes, leaving out PTTG1’s
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Figure 6 Saracatinib treatment combined with siRNA knockdown of PTTG1 decreases cytosolic FGF2 protein expression and slows cell
growth. (a) Efficient PTTG1 knockdown is confirmed by western blot assay. (b) Relative cell growth after 96 h of treatment is shown in the
comparison to untreated parental cells (*P-value < 0.05). (c) After siRNA transfection, ES2 cells were treated with 0 or 1μM saracatinib for
72 h. Cytosolic FGF2 concentration was normalized to nanogram FGF2 / milligram protein extract and represented in the comparison to
untreated parental cells (*P-value < 0.05). P, parental cells; NC, negative control scrambled siRNA transfection; +T, saracatinib treatment.
related homologs PTTG2 and PTTG3; Pearson’s correlation
r = +0.70 to +0.91, P-values <2 × 10−10 to 4 × 10−23),
which DAVID pathway analysis showed statistically signifi-
cant involvement in cell proliferation, cycle cell control, and
mitosis (GO_Biological Processes; corrected P-value <1 ×
10−52). The quality of negatively correlated genes was signif-
icantly worse (n = 142 genes; Pearson’s correlation r = –0.48
to –0.70, P-values <7 × 10−05 to 8 × 10−10) and did not iden-
tified any significant pathway enrichment.
PTTG1 cooperates with a proangiogenic factor, FGF2
One of PTTG1’s principal functions in the tumor microen-
vironment is promoting angiogenesis by activating growth
factors like FGF2.29,30 FGF2 is an also known proliferation
activating molecule in cells expressing FGFRs. Although
our gene expression microarrays did not show any cor-
relation between PTTG1 and FGF2 baseline mRNA levels
(Spearman’s correlation; r = –0.126, P = 0.681), we sought
to determine the interplay of FGF2 and PTTG1 protein levels
with saracatinib treatment. Cytosolic FGF2 and PTTG1 total
protein levels were evaluated after 72-h saracatinib treat-
ment in the selected cell lines (Figure 5; Supplementary
Figure S6). At baseline (no saracatinib treatment), FGF2 lev-
els were highly elevated in all sensitive cell lines except for
the EFO27 cell line compared with the resistant cell lines.
Saracatinib addition decreased the FGF2 levels prominently
in the sensitive lines in dose-dependent manner, which were
correlated with PTTG1 inhibition. Even the EFO27 cell line
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that had an extremely low intrinsic FGF2 level showed the
trend of FGF2 decline after 1 μM saracatinib treatment. In the
resistant cell lines, PTTG1 expression persisted after 72-h
treatment and FGF2 concentrations were relatively stable.
PTTG1 gene silencing decreases saracatinib resistance
and FGF2 levels in saracatinib-resistant cell lines
We wanted to test if silencing PTTG1 in a saracatinib-
resistant cell line affected proliferation and FGF2 expres-
sion. To assess these effects, PTTG1 was silenced in the
saracatinib-resistant cell lines ES2 (Figure 6) and MCAS
(Supplementary Figure S7) using siRNA plasmid con-
structs. Transfected ES2 was evaluated for PTTG1 expres-
sion (Figure 6a), saracatinib sensitivity to proliferation (Fig-
ure 6b), and FGF2 expression (Figure 6c). Untransfected
parental cell lines and a scrambled siRNA negative control
plasmid were used for comparison. The sensitive cell line,
SKOV3, showed no added effect of PTTG1 silencing, as its
expression level was low, and there was no additional effect
on cell proliferation or FGF2 levels (Figure 6). In untrans-
fected ES2 or ES2 transfected with the scrambled siRNA
negative control plasmid, saracatinib treatment alone had
only limited impact on cell growth or FGF2 levels. How-
ever, once PTTG1 protein levels were decreased by targeted
PTTG1 siRNA, saracatinib caused significant cell growth inhi-
bition, as well as downregulation of FGF2 levels.
DISCUSSION
PTTG1 was originally identified as a member of the securin
family, which controls genomic stability by regulating sis-
ter chromatid separation during mitosis.31 PTTG1’s SH-3
domain may mediate Src kinase activity through signal trans-
duction pathways and could potentially activate a variety
of growth factor pathways. Previous studies have demon-
strated that higher expression of PTTG1 was strongly asso-
ciated with tumor progression and worse prognosis in renal,
liver, and lung cancer.32–34 In addition, regulating FGF2 is
known to be another central function for PTTG1 in pituitary,
thyroid, and colon tumors.17,35–38 To our knowledge, this is
the first report demonstrating gene expression of PTTG1
and its association with sensitivity to a small molecule agent
targeting a specific kinase.
Vlotides et al. suggested there is a positive feedback regu-
lation between PTTG1 and FGF2.39 Our results suggest sen-
sitive cell lines may be more dependent on FGF2 expression
for proliferation than resistant cell lines. Saracatinib treatment
of sensitive ovarian cancer cell lines resulted in decreased
protein expression of PTTG1 and FGF2 as well as lower
phosphorylated Src levels. The analysis of the ovarian cancer
data set in TCGA yielded several important insights. PTTG1
mRNA expression was over a sevenfold range, although
there was no evidence for a relationship to patient survival.
However, there was a strong correlation with genes involved
in proliferation, cell division, and mitosis. Saracatinib inhi-
bition of sensitive cell lines may thus interfere with FGF2-
dependent proliferation. Two recent articles showed ovarian
cancer cell lines, with elevated FGFR2 expression, were sen-
sitive to preclinical FGFR targeting agents PD17307440 and
RPT835.41 We speculate that PTTG1 expression level may
Figure 7 A model for the possible functional relationship between
Src, P-Src, PTTG1, and FGF2.
not only be a correlative biomarker for saracatinib sensitivity
but also functionally important in regulating FGF2 expression
(Figure 7). However, an indirect effect may exist, with PTTG1
serving as a marker for FGF2-dependent proliferation.
In the upcoming era of “personalized medicine,” identify-
ing patients who would benefit from particular targeted ther-
apies is crucially important.6 Src kinase is a representative
molecular target known to be involved in diverse pathways
andmolecular interactions. In this study we demonstrate that
PTTG1 may play a key role in determining the efficacy of
saracatinib, a Src inhibitor, in ovarian cancer cell lines. In
contrast to dasatinib (which is FDA-approved), saracatinib is
thought to feature fewer off-target effects.24 Our data sug-
gest low expression of PTTG1 (mRNA or protein level) could
be a potential clinical biomarker to stratify ovarian cancer
patients (and potentially patients with other cancer types)
into targeted saracatinib trials. Dividing patients using mul-
tiple markers such as PTTG1 and FGFRs expression with a
proliferation index may help identify candidates for targeted
Src and FGFR combination therapy.
A Src inhibitor alone may have an impact on only a limited
number of cancers with low expression of PTTG1. However,
our findings suggest tumors refractory to Src-inhibitory ther-
apy could be sensitized when a Src inhibitor is combinedwith
other agents that target additional molecule(s) such as FGF2
and FGF receptors. Continuing in vitro studies, as well as val-
idations in mouse models, would be needed to better under-
stand the complicated relationship between PTTG1 and
Src-related pathways. In addition, combinatory treatment of
saracatinib and a FGFR tyrosine kinase inhibitor in sensitive
and resistant ovarian cancer cell lines should be examined.
Clinical and Translational Science
PTTG1 Levels Predict Saracatinib Sensitivity
Nakachi et al.
301
Acknowledgments. Research funding for this work was pro-
vided by The Adelson Foundation Ovarian Research Consortium and
AstraZeneca. Current address for I Nakachi: Division of Pulmonary
Medicine, Department of Medicine, Keio University School of Medicine,
Tokyo, Japan. Current address for MA Spillman: Texas Oncology, Sam-
mons Cancer Center, Baylor University Medical Center, Dallas, Texas. Cur-
rent address for RS Stearman and MW Geraci: Division of Pulmonary
Medicine, Department of Medicine, Indiana University School of Medicine,
Indianapolis, Indiana.
Author Contributions. I.N., B.A.H., M.A.S., J.L.R., M.W.G., and
R.S.S. wrote the article; I.N., B.A.H., M.A.S., C.D.C., L.E.H., M.W.G., and
R.S.S. designed the research; I.N., E.A.M., C.J.O., J.L.R., and R.S.S. per-
formed the research; I.N., B.A.H., M.A.S., E.A.M., C.J.O., J.L.R., C.D.C.,
and R.S.S. analyzed the data; L.E.H. contributed new reagents/analytical
tools.
Conflict of Interest. The authors declared no conflict of interest.
1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics 2014. CA. Cancer J. Clin. 64, 9–29
(2014).
2. Bast, R.C., Jr., Hennessy, B. & Mills, G.B. The biology of ovarian cancer: new opportunities
for translation. Nat. Rev. Cancer. 9, 415–428 (2009).
3. Aletti, G.D., Gallenberg, M.M., Cliby, W.A., Jatoi, A. & Hartmann, L.C. Current management
strategies for ovarian cancer.Mayo Clin. Proc. 82, 751–770 (2007).
4. Yap, T.A., Carden, C.P. & Kaye, S.B. Beyond chemotherapy: targeted therapies in ovarian
cancer. Nat. Rev. Cancer. 9, 167–181 (2009).
5. Banerjee, S. & Kaye, S.B. New strategies in the treatment of ovarian cancer: current clin-
ical perspectives and future potential. Clin. Cancer Res. 19, 961–968 (2013).
6. Huang, M., Shen, A., Ding, J. & Geng, M. Molecularly targeted cancer therapy: some
lessons from the past decade. Trends Pharmacol. Sci. 35, 41–50 (2014).
7. Yeatman, T.J. A renaissance for SRC. Nat. Rev. Cancer 4, 470–480 (2004).
8. Warmuth, M., Damoiseaux, R., Liu, Y., Fabbro, D. & Gray, N. SRC family kinases: potential
targets for the treatment of human cancer and leukemia.Curr. Pharm.Des.9, 2043–2059
(2003).
9. Summy, J.M. & Gallick, G.E. Src family kinases in tumor progression and metastasis.
Cancer Metastasis Rev. 22, 337–358 (2003).
10. Zhang, S. & Yu, D. Targeting Src family kinases in anti-cancer therapies: turning promise
into triumph. Trends Pharmacol. Sci. 33, 122–128 (2012).
11. Rexer, B.N. et al. Phosphoproteomic mass spectrometry profiling links Src family
kinases to escape from HER2 tyrosine kinase inhibition. Oncogene. 30, 4163–4174
(2011).
12. Nagaraj, N.S., Washington, M.K. & Merchant, N.B. Combined blockade of Src kinase and
epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resis-
tance of inhibition of pancreatic tumor growth. Clin. Cancer Res. 17, 483–493 (2011).
13. Green, T.P. et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Mol. Oncol. 3, 248–261 (2009).
14. McNeish, I.A.et al. A randomised, placebo-controlled trial of weekly paclitaxel and saraca-
tinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Ann. Oncol. 25, 1988–1995 (2014).
15. Simpkins, F. et al. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-
positive ovarian cancer models in vitro and in vivo. Clin. Cancer Res. 18, 5911–5923
(2012).
16. Pei, L. & Melmed, S. Isolation and characterization of a pituitary tumor-transforming gene
(PTTG).Mol. Endocrinol. 11, 433–441 (1997).
17. Tong, Y. & Eigler, T. Transcriptional targets for pituitary tumor-transforming gene-1. J.
Mol. Endocrinol. 43, 179–185 (2009).
18. Vlotides, G., Eigler, T. & Melmed, S. Pituitary tumor-transforming gene: physiology and
implications for tumorigenesis. Endocr. Rev. 28, 165–186 (2007).
19. Salehi, F., Kovacs, K., Scheithauer, B.W., Lloyd, R.V. & Cusimano, M. Pituitary tumor-
transforming gene in endocrine and other neoplasms: a review and update. Endocr. Relat.
Cancer 15, 721–743 (2008).
20. Zhang, X. et al. Structure, expression, and function of human pituitary tumor-transforming
gene (PTTG).Mol. Endocrinol. 13, 156–166 (1999).
21. Korch, C. et al. DNA profiling analysis of endometrial and ovarian cell lines reveals
misidentification, redundancy and contamination. Gynecol. Oncol. 127, 241–248 (2012).
22. Coldren, C.D. et al. Baseline gene expression predicts sensitivity to gefitinib in non-small
cell lung cancer cell lines.Mol. Cancer res. MCR 4, 521–528 (2006).
23. Tothill, R.W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer
linked to clinical outcome. Clin. Cancer Res. 14, 5198–5208 (2008).
24. Baselga, J. et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of
saracatinib in patients with solid tumors. Clin. Cancer Res. 16, 4876–4883 (2010).
25. Kaye, S.et al. Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or
carboplatin in patients with solid tumours. Br. J. Cancer 106, 1728–1734 (2012).
26. Beaufort, C.M. et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro
morphological subtypes. PLoS One 9, e103988 (2014).
27. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carci-
noma. Nature 474, 609–615 (2011).
28. Bowen, N.J. et al. Gene expression profiling supports the hypothesis that human ovarian
surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells.
BMC. Med. Genomics. 2, 71 (2009).
29. Kim, C.S., Ying, H., Willingham,M.C. & Cheng, S.Y. The pituitary tumor-transforming gene
promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis.
28, 932–939 (2007).
30. Heaney, A.P., Horwitz, G.A., Wang, Z., Singson, R. & Melmed, S. Early involvement of
estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expres-
sion in prolactinoma pathogenesis. Nat. Med. 5, 1317–1321 (1999).
31. Zou, H., McGarry, T.J., Bernal, T. & Kirschner, M.W. Identification of a vertebrate sister-
chromatid separation inhibitor involved in transformation and tumorigenesis. Science
285, 418–422 (1999).
32. Wondergem, B. et al. Expression of the PTTG1 oncogene is associated with aggressive
clear cell renal cell carcinoma. Cancer Res. 72, 4361–4371 (2012).
33. Liang, M. et al. Role of the pituitary tumor transforming gene 1 in the progression of
hepatocellular carcinoma. Cancer Biol. Ther. 11, 337–345 (2011).
34. Rehfeld, N. et al. The influence of the pituitary tumor transforming gene-1 (PTTG-1) on
survival of patients with small cell lung cancer and non-small cell lung cancer. J. Car-
cinog. 5, 4 (2006).
35. Heaney, A.P., Singson, R., McCabe, C.J., Nelson, V., Nakashima, M. & Melmed, S. Expres-
sion of pituitary-tumour transforming gene in colorectal tumours. Lancet. 355, 716–719
(2000).
36. Puri, R., Tousson, A., Chen, L. & Kakar, S.S.Molecular cloning of pituitary tumor transform-
ing gene 1 from ovarian tumors and its expression in tumors. Cancer Lett.163, 131–139
(2001).
37. Ishikawa, H., Heaney, A.P., Yu, R., Horwitz, G.A. & Melmed, S. Human pituitary tumor-
transforming gene induces angiogenesis. J. Clin. Endocrinol. Metab. 86, 867–874
(2001).
38. Chamaon, K., Kanakis, D., Mawrin, C., Dietzmann, K. & Kirches, E. Transcripts of PTTG and
growth factors bFGF and IGF-1 are correlated in pituitary adenomas. Exp. Clin. Endocrinol.
Diabetes 118, 121–126 (2010).
39. Vlotides, G., Chen, Y.H., Eigler, T., Ren, S.G. & Melmed, S. Fibroblast growth factor-2 aut-
ofeedback regulation in pituitary folliculostellate TtT/GF cells. Endocrinol. 150, 3252–
3258 (2009).
40. Itamochi, H. et al. Fibroblast growth factor receptor 2 is associated with poor overall
survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.
Int. J. Gynecol. Cancer 25, 570–576 (2015).
41. Tsimafeyeu, I. et al. Targeting FGFR2 with alofanib (RPT835) shows potent activity in
tumour models. Eur. J. Cancer 61, 20–28 (2016).
C© 2016 The Authors. Clinical and Translational Science
published by Wiley Periodicals, Inc. on behalf of Ameri-
can Society for Clinical Pharmacology and Therapeutics.
This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License,
which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and
is not used for commercial purposes.
Supplementary information accompanies this paper on the Clinical and Translational Science website.
(http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1752-8062)
www.wileyonlinelibrary/cts
